Hizentra is the first and only subcutaneous immunoglobulin proven to prevent CIDP relapse.
People taking Hizentra:
of Hizentra infusions were completed without any reported side effects
In a clinical trial, patients experienced fewer systemic side effects per infusion (like headache and nausea) with Hizentra than with IVIg
In clinical trials for Hizentra, the most common side effects were redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting.
†Patient advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Patient advocates are compensated by CSL Behring LLC. for their time and/or expenses.